For this reason, we comprehensively compared GE-biosafety level S1 TAT-CRE and S2 adenoviral Cre-recombinase (AD-CRE) to induce lung adenocarcinomas driven by a KrasG12D mutation and functional p53 depletion19,21. The gene discussed is TP53; the disease is lung adenocarcinoma.